2023/02/03 News Release (Presentation and Q&A Transcript) Telephone Conference for the 3rd Quarter of FY2022 Consolidated Result
2023/02/03 News Release Consolidated Financial Report for the First Three Quarters of the Fiscal Year Ending March 31, 2023
2023/02/03 News Release UBE Corporation Announces Revised Earnings Forecasts and Dividend Projections
2023/01/18 News Release UBE Corporation to Establish a New Company and Re-organize Group Companies in the U.S.
2022/09/26 News Release Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
2022/07/06 News Release UBE Corporation to Begin Basic Design for DMC and EMC Plant Construction in the U.S.
2022/06/10 News Release Santen and UBE announces U.S. Food and Drug Administration accepts resubmission of NDA for STN1011700 / DE-117 (omidenepag isopropyl) for treating glaucoma and ocular hypertension
2022/04/28 News Release UBE Corporation Announces Change of Representative Director and Personnel Change
2022/04/12 News Release UBE Group Announces New Medium-Term Targets by 2030 for Achieving Carbon Neutrality by 2050
2022/04/07 News Release UBE Corporation Selected as a Constituent of FTSE Blossom Japan Sector Relative Index